Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma

Inclusion Criteria: * \> 18 years * HCC diagnosis : * histologically or cytologically proven HCC * or association of the three following criteria: * cirrhosis * typical measurable mass (\> 3cm, by 2 methods) * serum alpha-foetoprotein (AFP) ≥500 µg/L * Cancer Liver Italian Program (CLIP) score : 0 to 3 * Not eligible for specific treatment (surgery, percutaneous ablation or chemo-embolization) Exclusion Criteria: * Glycemia \> 2.5 g/L or hypoglycemia * Extra hepatic life-threatening disease * Serum creatinin\> 120 µmol/L * Prothrombin time \< 50 % * Platelet count \< 50.000 /µL * Symptomatic cholelithiasis * Non-measurable tumor